Skip to main content
. 2023 Apr 7;15(5):2485–2496. doi: 10.21037/jtd-22-1546

Table 4. Diagnostic performance of US-guided PCNB.

Biopsy result Final result Total
Malignancy Benign
Malignancy 453 (79.2%) 0 453
Benign 55 (9.6%) 64 (11.2%) 119
Total 508 64 572

Non-diagnostic results of US-guided PCNB were considered as false positives, resulting in discrepancy of malignancy rate of final diagnosis. US, ultrasound; PCNB, percutaneous core needle biopsy.